

Sorrento Therapeutics, Inc.  
Form 8-K  
January 12, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**  
**FORM 8-K**  
**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 12, 2015**

**SORRENTO THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation or organization)	<b>001-36150</b> (Commission File Number)	<b>33-0344842</b> IRS Employer Identification No.)
	<b>6042 Cornerstone Ct. West, Suite B</b>	
	<b>San Diego, CA 92121</b>	

(Address of principal executive offices)

Registrant's telephone number, including area code: **(858) 210-3700**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Edgar Filing: Sorrento Therapeutics, Inc. - Form 8-K

- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On January 12, 2015, Sorrento Therapeutics, Inc. (the Company ) announced that over 80 patients randomized in the ongoing TRIBECA (TRIAL establishing bioequivalence [BE] between Cynviloq and Albumin-bound paclitaxel\*) registrational trial have been dosed. The Company intends to continue enrolling all qualified patients in the current screening process and anticipates having the last patient in by the end of January. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

The Company intends on making presentations to third parties using the corporate presentation attached as Exhibit 99.2 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

The following exhibits are filed with this Current Report on Form 8-K:

**Exhibit  
No.**

**Description**

99.1	Press release of Sorrento Therapeutics, Inc., dated January 12, 2015
99.2	January 2015 Corporate Presentation of Sorrento Therapeutics, Inc. SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 12, 2015

SORRENTO THERAPEUTICS, INC.

By: /s/ Henry Ji  
Name: Henry Ji  
Title: President and Chief Executive Officer